US › Healthcare

Can Fite Biopharma Ltd ADR (CANF)

US · Healthcare · Biotechnology

$2.240.00%

Last close · 2026-09-17

Latest quarter · ended 2025-12-31

Revenue

$101,500

Revenue YoY

-43.3%

Net profit

$-2.5M

EPS

$0.00

EPS estimate

$-2.40

Net margin

-2,439.4%

EPS came in at 0.00 against a street estimate of -2.40 — a beat of 100.0%.

Key statistics

Market cap

$5.0M

Forward P/E

3.0

P/B

1.03

Book value

$2.27

EPS (TTM)

$-4.65

52-week high

$13.40

52-week low

$2.16

50-day MA

$3.19

200-day MA

$3.79

Beta

-0.04

Analyst view

Analysts rate Can Fite Biopharma Ltd ADR a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.00.

Shareholding

Institutions

1.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Can Fite Biopharma Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.